An experimental oral PCSK9 inhibitor is associated with LDL-C reductions that could prove to be a game-changer for patient care. 

New Jersey-based Zydus Pharmaceuticals has recalled nearly 23,000 bottles of its icosapent ethyl capsules due to leakage issues that may have weakened their effectiveness. 

The cardiologist at the head of an influential CDC panel sees serious problems with modern vaccine policies. While many experts seem to disagree, one organization has jumped to his defense. 

New drug allows patients to self-treat PSVT. About 2 million people in the U.S. have been diagnosed with condition.

Early research suggests a single injection could reduce both brain damage and inflammation if delivered after a patient experiences a stroke. Much more research is still needed, but the new therapy showed significant potential. 

Most patients hospitalized for HFrEF are still not being prescribed quadruple medical therapy at discharge. Even those who are, researchers noted, still face a high risk of dying or returning to the hospital for heart failure-related symptoms. 

The American Stroke Association's first major update in 7 years highlights the importance of coordinated care and expands patient access to critical treatments. It also includes the first detailed recommendations for treating stroke in pediatric patients.

Cannabis use has been linked to multiple cardiovascular risks, but less is known about how it may affect patients who undergo major cardiac surgery.